X0306 4 2016-02-03 1 0001432732 TriVascular Technologies, Inc. TRIV 0001356950 Scopa James Paul C/O MPM ASSET MANAGEMENT 601 GATEWAY BLVD., SUITE 350 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2016-02-03 4 D 0 1776692 D 0 I See Footnote The shares were held as follows: 1,665,193 by MPM BioVentures IV-QP, L.P. ("BV IV QP"), 64,151 by MPM BioVentures IV GmbH & Co. Beteiligungs KG ("BV IV KG") and 47,348 by MPM Asset Management Investors BV4 LLC ("AM BV4"). MPM BioVentures IV GP LLC and MPM BioVentures IV LLC ("BV LLC") are the direct and indirect general partners of BV IV QP and BV IV KG and BV LLC is the manager of AM BV4. The Reporting Person is a member of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. These shares were disposed of pursuant to the merger agreement between the issuer and Endologix, Inc. (such transaction, the "Merger"). In connection with the closing of the Merger, the reporting person received 0.631 share of Endologix common stock and $0.34 in cash for each share of issuer common stock held by such reporting person, for a total consideration of $4.95 per share based upon the closing price of Endologix common stock on February 2, 2016. /s/ James Paul Scopa 2016-02-04